The financing round will support uBiome's ongoing efforts to commercialize its clinical microbiome analysis, sexually-transmitted disease, and gut wellness tests.
The collaborators plan to collect samples that will allow them insight into participants' microbiomes in order to understand disease mechanisms over time.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
